Report Phase 3 readouts for Aflibercept 8mg
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 10 Jan 2022
- Due
- 31 Dec 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Ph3 readouts for Aflibercept 8mg expected 2H22”
What we found
Evidence strength A What the grades mean
A January 2023 filing describes positive pivotal Phase 3 data for aflibercept 8 mg in wet AMD and DME as 2022 advances, so the readouts appear to fall within 2022. The exact date is not stated.
-
A Regeneron Pharmaceuticals 8-K filed 2023-01-09
“Meaningful advances across therapeutic areas in 2022 17 Ophthalmology Immunology Oncology Broader Pipeline EYLEA (VEGF Trap)” ✓ confirmed on the page
-
A Regeneron Pharmaceuticals 8-K filed 2023-01-09
“Positive pivotal data in wet Age - related Macular Degeneration and Diabetic Macular Edema” ✓ confirmed on the page
-
A Regeneron Pharmaceuticals 10-K filed 2023-02-06
“Reported that Phase 3 trials in wet AMD and DME met their primary endpoints” ✓ confirmed on the page
Market reaction: the shares moved -5.6% against the S&P 500 over the three sessions around the disclosure (6 Jan 2023 to 11 Jan 2023). What this measures
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Project other
- Indicative materiality
- Low rules
- Action
- Report
- Deliverable
- Phase 3 readouts for Aflibercept 8mg
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Regeneron Pharmaceuticals? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-REGN-006338 · Corrections policy